• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    9/26/23 1:31:02 PM ET
    $APLT
    $CADL
    $DMK
    $FEMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APLT alert in real time by email

    Gainers

    • Soleno Therapeutics (NASDAQ:SLNO) shares increased by 426.2% to $23.31 during Tuesday's regular session. Soleno Therapeutics's stock is trading at a volume of 32.5 million shares as of 13:30 EST. This is 51215.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $232.9 million.
    • Femasys (NASDAQ:FEMY) shares rose 272.43% to $1.24. As of 13:30 EST, Femasys's stock is trading at a volume of 147.8 million, which is 3882.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.6 million.
    • DMK Pharmaceuticals (NASDAQ:DMK) stock rose 160.42% to $1.18. Trading volume for this security as of 13:30 EST is 37.7 million, which is 23977.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $11.0 million.
    • Immunovant (NASDAQ:IMVT) shares moved upwards by 101.08% to $40.78. Trading volume for Immunovant's stock is 29.8 million as of 13:30 EST. This is 2654.1% of its average full-day volume over the last 100 days. The company's market cap stands at $5.3 billion.
    • Intercept Pharma (NASDAQ:ICPT) shares rose 78.87% to $18.68. The current volume of 30.6 million shares is 3295.4% of Intercept Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $780.2 million.
    • Applied Therapeutics (NASDAQ:APLT) shares moved upwards by 29.74% to $2.66. The current volume of 1.2 million shares is 198.2% of Applied Therapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $167.8 million.

    Losers

    • TransCode Therapeutics (NASDAQ:RNAZ) shares declined by 71.7% to $0.72 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 13.7 million, which is 677.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.4 million.
    • Fresh2 Group (NASDAQ:FRES) stock fell 16.67% to $1.65. The company's market cap stands at $10.3 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares declined by 16.11% to $0.22. Trading volume for Novo Integrated Sciences's stock is 12.3 million as of 13:30 EST. This is 27.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $35.4 million.
    • Candel Therapeutics (NASDAQ:CADL) shares fell 15.19% to $0.95. Candel Therapeutics's stock is trading at a volume of 200.1K shares as of 13:30 EST. This is 1223.1% of its average full-day volume over the last 100 days. The company's market cap stands at $27.4 million.
    • Know Labs (AMEX:KNW) stock declined by 14.8% to $0.38. Trading volume for Know Labs's stock is 304.3K as of 13:30 EST. This is 248.1% of its average full-day volume over the last 100 days. The company's market cap stands at $19.8 million.
    • Vaccitech (NASDAQ:VACC) stock decreased by 14.25% to $2.71. Trading volume for this security as of 13:30 EST is 1.7 million, which is 288.4% of its average full-day volume over the last 100 days. The company's market cap stands at $104.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLT
    $CADL
    $DMK
    $FEMY

    CompanyDatePrice TargetRatingAnalyst
    Immunovant Inc.
    $IMVT
    1/6/2026$50.00Peer Perform → Outperform
    Wolfe Research
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Candel Therapeutics Inc.
    $CADL
    10/28/2025$15.00Overweight
    Stephens
    Immunovant Inc.
    $IMVT
    10/14/2025$16.00Hold
    Truist
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    More analyst ratings

    $APLT
    $CADL
    $DMK
    $FEMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,996 worth of shares (550,458 units at $5.45) (SEC Form 4)

    4 - Candel Therapeutics, Inc. (0001841387) (Issuer)

    2/26/26 7:38:59 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Roivant Sciences Ltd. bought $349,999,986 worth of shares (16,666,666 units at $21.00), increasing direct ownership by 17% to 113,317,007 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    12/12/25 5:17:21 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Roivant Sciences Ltd. bought $336,900,200 worth of shares (16,845,010 units at $20.00), increasing direct ownership by 21% to 96,650,341 units (SEC Form 4)

    4 - Immunovant, Inc. (0001764013) (Issuer)

    1/15/25 4:36:38 PM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Femasys Inc.

    SCHEDULE 13G - FEMASYS INC (0001339005) (Subject)

    3/18/26 5:00:01 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Candel Therapeutics Inc.

    SCHEDULE 13D/A - Candel Therapeutics, Inc. (0001841387) (Subject)

    3/18/26 4:23:14 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 8-K filed by Soleno Therapeutics Inc.

    8-K - SOLENO THERAPEUTICS INC (0001484565) (Filer)

    3/16/26 9:28:28 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Pharmacyte Biotech, Inc.

    4 - FEMASYS INC (0001339005) (Issuer)

    3/18/26 5:00:03 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Silverman Joshua

    4 - FEMASYS INC (0001339005) (Issuer)

    3/18/26 5:00:02 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Fulk Jennifer was granted 39,200 shares (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:59:56 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

    Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or CAN-2409) surviving beyond 24 months, despite prior inadequate response to immune checkpoint inhibitors (ICI) and multiple adverse baseline prognostic factors.Among the patients surviving beyond 24 months and with PD-L1 status available, (17/20) 85% had baseline PD-L1 tumor proportion scores (TPS) below 50% (a population typically less responsive to ICI), supporting the potential of aglatimagene to upregulate PD-L1 in the tumor microenvironment and convert

    3/17/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibitor (ICI) treatment, in Q2 2026Company plans to submit a Biologics License Application (BLA) for aglatimagene in localized, intermediate-to high-risk prostate cancer in Q4 2026Company announced investigational new drug (IND) clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma (rHGG) to support enabling work for a potential future randomized controlled phase 2 dose regimen finding study.Entered into a $130 million term loan facility with Tri

    3/12/26 8:05:00 AM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-8) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 02/24/2022. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    2/25/22 4:36:46 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for OCALIVA issued to INTERCEPT PHARMS INC

    Submission status for INTERCEPT PHARMS INC's drug OCALIVA (SUPPL-7) with active ingredient OBETICHOLIC ACID has changed to 'Approval' on 05/26/2021. Application Category: NDA, Application Number: 207999, Application Classification: Labeling

    5/27/21 5:23:24 AM ET
    $ICPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Immunovant Sciences upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Immunovant Sciences from Peer Perform to Outperform and set a new price target of $50.00

    1/6/26 8:39:27 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Applied Therapeutics downgraded by Robert W. Baird

    Robert W. Baird downgraded Applied Therapeutics from Outperform to Neutral

    12/12/25 9:22:39 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Applied Therapeutics from Outperform to Market Perform and set a new price target of $1.00

    12/3/25 8:27:30 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Financials

    Live finance-specific insights

    View All

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soleno Therapeutics to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026, at 4:30 PM ET

    REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Wednesday, February 25, 2026Time:4:30 PM Eastern TimeUnited States:1-800-717-1738Internation

    2/11/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

    IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

    2/6/26 7:00:00 AM ET
    $IMVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLT
    $CADL
    $DMK
    $FEMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Candel Therapeutics Inc.

    SC 13G - Candel Therapeutics, Inc. (0001841387) (Subject)

    12/17/24 12:30:40 PM ET
    $CADL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care